Fu Yu Corp doubles down on biomedical bet
Added capabilities enable it to value-add and engage new customers, as well as pursue further collaborations with existing customers
Add BT as a preferred source
PRECISION plastic parts manufacturer Fu Yu Corp aims to increase sales from its biomedical segment to more than half of the group’s revenue within the next three to five years, up from the current 3 per cent, supported by the launch of its smart factory and new product design capabilities.
“The 3 per cent is evidence that it’s there,” said group chief executive officer David Seow. “We haven’t moved the needle yet, because for some of the capabilities that we’ve got since last year, it takes time. But the signs are there.”
The global biomedical devices market reportedly reached about US$600 billion in 2023, and is expected to grow 6 to 7 per cent annually, Seow said. It is “clearly a sunrise industry”, compared with Fu Yu’s other sectors, such as printing and imaging, consumer, automotive, and medical (where it produces casings), he added.
TRENDING NOW
Canada’s fight with the US has far bigger stakes than trade
Can Bali swop beach capital for global capital without the skyscrapers?
Stripe’s Apac business should grow faster than any other region, says its chief revenue officer
What’s luck got to do with it? Everything, says Malaysian jewellery king Tomei’s chief
